eClinical solutions Market Size By Solution (Randomization and Trial Supply Management (RTSM), Clinical Data Management System (CDMS), Clinical Trial Management System (CTMS), Electronic Clinical Outcome Assessment (eCOA), Electronic Trial Master Files (E

eClinical solutions Market Size By Solution (Randomization and Trial Supply Management (RTSM), Clinical Data Management System (CDMS), Clinical Trial Management System (CTMS), Electronic Clinical Outcome Assessment (eCOA), Electronic Trial Master Files (ETMF), Electronic Data Capture (EDC)), By Delivery Mode (Licensed Enterprise (On-premise) solutions, Cloud-based (SAAS) solutions, Web-hosted (On-demand) solutions), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), By End-use (Contract Research Organizations (CROs), Medical Device Companies, Pharma/Biotech Companies, Hospitals & Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028

The global eClinical solutions market is expected to grow at a significant rate through 2028 driven by increasing investment in clinical research. Additionally, robust adoption of new technologies is set to further propel industry expansion over the forecast timeline.

Recently, leading companies have been collaborating with global businesses to conduct clinical trials on a larger scale. As a result, surging focus on the development of novel products has been favorable for the growth of the eClinical solutions market.

For instance, in April 2021, eClinical Solutions LLC, a leading supplier of cloud-based business software as well as software-driven clinical data services across the globe that expedite digital clinical initiatives, announced that Translational Research in Oncology (TRIO), an international academic clinical research organization (CRO), has chosen eClinical's Elluminate clinical data platform to modernize trial processes throughout its network of 700+ cancer centers. Life sciences companies, especially CROs, are increasingly using Elluminate to support digital transformation plans by integrating data sources into a single platform that allows for real-time analysis and integration of clinical data from ingestion to insights.

The eClinical solutions market has been segmented in terms of solution, delivery mode, clinical trial phase, end-use, and region. Based on solution, the industry has been further bifurcated into randomization and trial supply management, clinical data management system, clinical trial management system, electronic clinical outcome assessment, electronic trial master files, electronic data capture, and others. In 2021, the clinical data management system sub-segment was valued at over USD 803.4 million and is slated to witness strong growth through 2028.

With respect to delivery mode, the eClinical solutions market has been classified into cloud-based (SaaS) solutions, licensed enterprise (on-premise) solutions, and web-hosted (on-demand) solutions. In 2021, the web-hosted (on-demand) solutions sub-segment recorded a market share of 51.2% and is projected to grow substantially over 2022-2028. Owing to increasing demand for web-hosted solutions, the industry is expected to grow at an exponential rate through the forecast timeframe.

Based on clinical trial phase, the eClinical solutions industry has been classified into phase I, phase II, phase III, and phase IV. The phase IV sub-segment is anticipated to reach a market revenue of around USD 3,439.4 million by 2028.

In terms of end-use, the sector is categorized into medical device companies, contract research organizations (CROs), hospitals & clinics, pharma/biotech companies, and others. The hospitals & clinics sub-segment is anticipated to be valued at about USD 2,065.6 million by 2028.

In the regional landscape, the Latin America eClinical solutions industry recorded a market share of more than 8.6% in 2021 and is speculated to witness notable growth by 2028. Meanwhile, the Middle East & Africa eClinical solutions market is poised to experience steady growth at a rate of around 12.6% through the forecast timeframe.